A chart always shows what the insiders know (let me tell you what they know about DRTS)

DRTS is a revolutionary cancer treatment that is at the turning point from a clinical-stage pre-revenue company to a commercial platform. The patented tech delivers alpha radiation into the tumors, killing the cancer cells while sparing healthy tissue (and even awakens the immune system and teaches it to fight cancer elsewhere in the body). It’s effective against all solid tumors, even the most high unmet needs like Pancreas and GBM (both have active in-human FDA trials with amazing results). DRTS has 55+ clinical sites worldwide, FDA Breakthrough Device Designation, fully funded with an experienced management team. What the insiders know is that the PMDA (the Japanese FDA) is set to approve the treatment, and it’s the hardest approval to get making the FDA almost a formality (and potentially coming this year as well). They also know that this weekend at the MHNCS a professor shared with fellow oncologists that the trial he is leading, a combination therapy with Keytruda the #1 selling drug in the world, has significantly boosted the results in small sample size from 19% response rate for Keytruda alone, to effectively 100%(!) response rate when adding the DRTS treatment. And the five IDEs the FDA already approved for DRTS are probably not the only ones to get announced this year. NFA and DYOR, but 2026 will be full of DRTS catalysts, some expected some unexpected, and the chart says the next one ain’t too far away.